Stephen Piccolo

Dr. Stephen Piccolo

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2017 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
HBHamid Bolouri
Hamid Bolouri
JFJason E Farrar
Jason E Farrar
TTTimothy Triche
Timothy Triche
RRRhonda E Ries
Rhonda E Ries
ELEmilia L Lim
Emilia L Lim
SMSoheil Meshinchi
Soheil Meshinchi

24 July 2015 in Bioinformatics
Verified
Journal Article
Open access
PDF file
MRMumtahena Rahman
Mumtahena Rahman
LJLaurie K. Jackson
Laurie K. Jackson
WJW. Evan Johnson
W. Evan Johnson
DLDean Y. Li
Dean Y. Li
ABAndrea H. Bild
Andrea H. Bild
SPStephen Piccolo
Stephen Piccolo
Motivation: The Cancer Genome Atlas (TCGA) RNA-Sequencing data are used widely for research. TCGA provides ‘Level 3’ data, which have been processed using a pipeline specific to that resource. However, we have found using experimentally derived data that this pipeline produces gene-expression values that vary considerably across biological replicates. In addition, some RNA-Sequencing analysis tools require integer-based read counts, which are not provided with the Level 3 data. As an alternative, we have reprocessed the data for 9264 tumor and 741 normal samples across 24 cancer types using the Rsubread package. We have also collated corresponding clinical data for these samples. We provide these data as a community resource. Results: We compared TCGA samples processed using either pipeline and found that the Rsubread pipeline produced fewer zero-expression genes and more consistent expression levels across replicate samples than the TCGA pipeline. Additionally, we used a genomic-signature approach to estimate HER2 (ERBB2) activation status for 662 breast-tumor samples and found that the Rsubread data resulted in stronger predictions of HER2 pathway activity. Finally, we used data from both pipelines to classify 575 lung cancer samples based on histological type. This analysis identified various non-coding RNA that may influence lung-cancer histology. Availability and implementation: The RNA-Sequencing and clinical data can be downloaded from Gene Expression Omnibus (accession number GSE62944). Scripts and code that were used to process and analyze the data are available from https://github.com/srp33/TCGA_RNASeq_Clinical. Contact:stephen_piccolo@byu.edu or andreab@genetics.utah.edu Supplementary information: Supplementary material is available at Bioinformatics online.

11 July 2016 in GigaScience
Verified
Journal Article
Open access
PDF file
SPStephen Piccolo
Stephen Piccolo
MFMichael B. Frampton
Michael B. Frampton
When reporting research findings, scientists document the steps they followed so that others can verify and build upon the research. When those steps

1 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBSamuel W. Brady
Samuel W. Brady
JMJasmine A. McQuerry
Jasmine A. McQuerry
YQYi Qiao
Yi Qiao
SPStephen Piccolo
Stephen Piccolo
GSGajendra Shrestha
Gajendra Shrestha
ABAndrea H. Bild
Andrea H. Bild
Metastatic breast cancer remains challenging to treat, and most patients ultimately progress on therapy. This acquired drug resistance is largely due to drug-refractory sub-populations (subclones) within heterogeneous tumors. Here, we track the genetic and phenotypic subclonal evolution of four breast cancers through years of treatment to better understand how breast cancers become drug-resistant. Recurrently appearing post-chemotherapy mutations are rare. However, bulk and single-cell RNA sequencing reveal acquisition of malignant phenotypes after treatment, including enhanced mesenchymal and growth factor signaling, which may promote drug resistance, and decreased antigen presentation and TNF-α signaling, which may enable immune system avoidance. Some of these phenotypes pre-exist in pre-treatment subclones that become dominant after chemotherapy, indicating selection for resistance phenotypes. Post-chemotherapy cancer cells are effectively treated with drugs targeting acquired phenotypes. These findings highlight cancer’s ability to evolve phenotypically and suggest a phenotype-targeted treatment strategy that adapts to cancer as it evolves.

16 December 2016 in Scientific Reports
Verified
Journal Article
Open access
PTPj Tatlow
Pj Tatlow
SPStephen Piccolo
Stephen Piccolo
Public compendia of sequencing data are now measured in petabytes. Accordingly, it is infeasible for researchers to transfer these data to local computers. Recently, the National Cancer Institute began exploring opportunities to work with molecular data in cloud-computing environments. With this approach, it becomes possible for scientists to take their tools to the data and thereby avoid large data transfers. It also becomes feasible to scale computing resources to the needs of a given analysis. We quantified transcript-expression levels for 12,307 RNA-Sequencing samples from the Cancer Cell Line Encyclopedia and The Cancer Genome Atlas. We used two cloud-based configurations and examined the performance and cost profiles of each configuration. Using preemptible virtual machines, we processed the samples for as little as $0.09 (USD) per sample. As the samples were processed, we collected performance metrics, which helped us track the duration of each processing step and quantified computational resources used at different stages of sample processing. Although the computational demands of reference alignment and expression quantification have decreased considerably, there remains a critical need for researchers to optimize preprocessing steps. We have stored the software, scripts, and processed data in a publicly accessible repository (https://osf.io/gqrz9).

15 January 2020 in Biology Direct
Verified
Journal Article
Open access
PDF file
GSG. Rex Sumsion
G. Rex Sumsion
MBMichael S. Bradshaw
Michael S. Bradshaw
JBJeremy T. Beales
Jeremy T. Beales
EFEmi Ford
Emi Ford
GCGriffin R. G. Caryotakis
Griffin R. G. Caryotakis
SPStephen Piccolo
Stephen Piccolo
Background: Drug-induced liver injury (DILI) is a serious concern during drug development and the treatment of human disease. The ability to accurately predict DILI risk could yield significant improvements in drug attrition rates during drug development, in drug withdrawal rates, and in treatment outcomes. In this paper, we outline our approach to predicting DILI risk using gene-expression data from Build 02 of the Connectivity Map (CMap) as part of the 2018 Critical Assessment of Massive Data Analysis CMap Drug Safety Challenge.Results: First, we used seven classification algorithms independently to predict DILI based on gene-expression values for two cell lines. Similar to what other challenge participants observed, none of these algorithms predicted liver injury on a consistent basis with high accuracy. In an attempt to improve accuracy, we aggregated predictions for six of the algorithms (excluding one that had performed exceptionally poorly) using a soft-voting method. This approach also failed to generalize well to the test set. We investigated alternative approaches—including a multi-sample normalization method, dimensionality-reduction techniques, a class-weighting scheme, and expanding the number of hyperparameter combinations used as inputs to the soft-voting method. We met limited success with each of these solutions.Conclusions: We conclude that alternative methods and/or datasets will be necessary to effectively predict DILI in patients based on RNA expression levels in cell lines.Reviewers: This article was reviewed by Paweł P Labaj and Aleksandra Gruca (both nominated by David P Kreil).